Internal Reference Number: FOI_8591
Date Request Received: 15/04/2025 00:00:00
Date Request Replied To: 09/05/2025 00:00:00
This response was sent via: By Email
Request Summary: new biologic and targeted medications - Gastroenterology
Request Category: Researcher
| Question Number 1: . How many patients were treated in March 2025 (or latest available month) by the gastroenterology department with the following biologic drugs? • Etrasimod • Filgotinib • Golimumab • Mirikizumab • Ozanimod • Risankizumab • Tofacitinib • Upadacitinib • Ustekinumab (Stelara) • Ustekinumab Biosimilar • Vedolizumab | |
| Answer To Question 1: Patients on treatment in April 2025: • Etrasimod 0 • Filgotinib <5 • Golimumab <5 • Mirikizumab 6 • Ozanimod 0 • Risankizumab 11 • Tofacitinib <5 • Upadacitinib 29 • Ustekinumab (Stelara) 8 • Ustekinumab Biosimilar 83 • Vedolizumab 60 | |
| Question Number 2: How many patients were treated in March 2025 (or latest available month) for Crohn's disease with the following biologic drugs? • Golimumab • Risankizumab • Upadacitinib • Ustekinumab (Stelara) • Ustekinumab Biosimilar • Vedolizumab | |
| Answer To Question 2: Patients treated in April 2025: • Golimumab <5 • Risankizumab 11 • Upadacitinib 16 • Ustekinumab (Stelara) 6 • Ustekinumab Biosimilar 71 • Vedolizumab 16 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
